Top 10 Pramipexole (Mirapex) Generic Manufacturers in India
The pharmaceutical market in India is experiencing significant growth, driven by increasing demand for generic medications, especially for chronic conditions like Parkinson’s disease. The global market for Pramipexole, marketed as Mirapex, is expected to reach USD 1.5 billion by 2025, with India being a major player in the production of generic drugs. In 2021, India accounted for approximately 20% of the global generic drug market, indicating a robust manufacturing base that caters both to domestic and international markets.
1. Sun Pharmaceutical Industries Ltd.
Sun Pharma is one of the largest generic pharmaceutical companies in India, with a market share of around 18% in the Indian formulations market. The company produces Pramipexole under the brand name Sunpramipexole. In FY 2022, Sun Pharma reported a revenue of USD 4.5 billion, making it a key player in the generics segment.
2. Lupin Pharmaceuticals
Lupin is well-known for its extensive range of generic medications, including Pramipexole. The company holds approximately 10% of the Indian market share and generated revenue of USD 2.5 billion in FY 2022. Lupin’s strong R&D capabilities help maintain its competitive edge in the generic market.
3. Aurobindo Pharma
Aurobindo Pharma is a significant manufacturer of generic pharmaceuticals, including Pramipexole, with a market share of about 8%. The company reported a revenue of USD 1.9 billion in the last fiscal year, supported by its robust export operations, which account for nearly 50% of its total sales.
4. Dr. Reddy’s Laboratories
Dr. Reddy’s is a prominent player in the Indian pharmaceutical market, known for its generics, including Pramipexole. With a market share of around 7%, the company achieved revenues of USD 2.1 billion in FY 2022. Its strong focus on R&D has bolstered its presence in both domestic and international markets.
5. Cipla Limited
Cipla is another leading pharmaceutical company that produces Pramipexole. It commands a market share of approximately 6% in the Indian pharmaceutical sector. In FY 2022, Cipla reported a revenue of USD 2.2 billion, driven by its diversified product portfolio and strong global presence.
6. Zydus Cadila
Zydus Cadila is a major player in the generic pharmaceutical sector, with a market share of about 5%. The company reported revenues of USD 2 billion in FY 2022, supported by a wide portfolio that includes Pramipexole. Zydus focuses heavily on research and development to innovate and expand its offerings.
7. Torrent Pharmaceuticals
Torrent Pharmaceuticals is a prominent manufacturer of generic drugs, including Pramipexole, with a market share of around 4%. The company generated revenues of USD 1.5 billion in FY 2022, leveraging its strong distribution networks to capture both domestic and international markets.
8. Glenmark Pharmaceuticals
Glenmark is known for its diverse portfolio, including Pramipexole. The company has a market share of about 3% and achieved revenues of USD 1.4 billion in FY 2022. Glenmark’s aggressive R&D strategy allows for a steady pipeline of new generics.
9. Alkem Laboratories
Alkem Laboratories holds a market share of around 3% in the Indian pharmaceutical market. The company reported revenues of USD 1.3 billion in the last fiscal year, supported by a strong presence in chronic disease management products, including Pramipexole.
10. Mylan Laboratories
Mylan, now part of Viatris, is a well-established manufacturer of generic medications, including Pramipexole. The company has a market share of approximately 2% and reported revenues of USD 1.8 billion in FY 2022, catering to a global audience with its high-quality generic products.
Insights
The generic pharmaceuticals market in India is projected to grow at a CAGR of around 11% from 2022 to 2027, driven by increasing healthcare needs, especially for chronic diseases like Parkinson’s. The demand for Pramipexole is expected to rise due to the growing aging population and the prevalence of neurological disorders. Indian manufacturers are likely to benefit from favorable government policies supporting generic drug production and exports, which currently represent about 60% of India’s total pharmaceutical output. As competition intensifies among these top manufacturers, innovations in formulation and delivery systems will play a crucial role in capturing market share.
In conclusion, the Indian pharmaceutical sector, particularly in the realm of generics like Pramipexole, is poised for significant growth, backed by strong R&D capabilities and a commitment to quality.
Related Analysis: View Previous Industry Report
